Granules India — the integrated generic maker climbing out of commodity

The Pulse

Granules makes some of the most commoditised molecules on earth — paracetamol and metformin, the world’s most ordinary pills — and earns ~22% operating margins doing it, because it owns every step from raw chemical to finished tablet. FY26 was the year it broke out of a two-year plateau: revenue crossed ₹5,000 crore for the first time (+20% to ₹5,366 crore), six straight quarters of sequential growth, gross margin up to 65% (from 50% four years ago) on a deliberate shift into complex, harder-to-make products. A ₹665 crore equity raise then cut net debt to almost nothing (0.34× EBITDA). Two things keep it from being a clean victory: the business has been quietly choosing growth-with-debt over cash returns, with working capital ballooning to a 256-day cycle; and a US FDA inspection at its main plant has dragged unresolved for over two years. At 31× earnings for a mid-teens-return generic maker, the market is paying for the breakout to continue.

The Business

Granules sits across all three rungs of a pill’s making: the API (the active chemical), the PFI (a Granules signature — a ready-to-press intermediate blend that most rivals neither make nor buy), and the finished dosage (the packaged tablet). That full vertical integration is the entire financial trick. A pure paracetamol API trader earns wafer-thin, volatile spreads; Granules captures margin at three stages instead of one, which is why a maker of the world’s most generic molecules runs low-twenties operating margins. Finished dosages are now 74% of revenue, the business is ~95% export-driven, and the US is the engine — its Virginia arm (GPI) has climbed to the 27th-largest US generic company and 4th in controlled substances.

The strategic story of recent years is a deliberate climb up the value chain. The cheap legacy molecules are being deprioritised in favour of complex, limited-competition generics — which jumped from 27% to nearly half of contribution in a single year. The crown jewel is the controlled-substances/ADHD franchise (generic Vyvanse, a tentative approval for generic Adzenys stuck in litigation), where Granules’ clean DEA-compliance history is itself a moat — it wins manufacturing quota that latecomers can’t. Europe is the breakout geography, up 81% to ~15% of revenue.

The cost of this model shows on the balance sheet. Owning every stage means holding inventory at every stage — inventory days have ballooned to 326, the cash-conversion cycle to 256, and interest costs have quadrupled to ~₹114 crore on rising debt (since cut hard by the equity raise). Ownership has shifted too: promoters down from 42% to 38% over two years, with domestic institutions stepping in from ~7% to 17%. This is a sound, cash-backed franchise — but a heavier, more capital-hungry one than an asset-light formulations marketer.

How Management Thinks

The Chairman, Dr Krishna Prasad Chigurupati, returned to full-time command after the CEO resigned, and his daughter Priyanka (Executive Director) increasingly fronts the commercial and regulatory answers — a visible generational handoff. The tone is calm, plain-spoken, occasionally folksy (“let’s hear it from the horse’s mouth”), and the candour is genuine where it counts. On the FDA delay, the Chairman was blunt: “we thought they’d come for a quick re-inspection… we can’t read the FDA’s mind.” On the niche DCDA chemical plant, he admitted Chinese competitors “started reducing prices drastically” and forced them to chase. On FY27 margins, with Middle-East-driven input inflation biting and price pass-through still pending, they explicitly declined to commit to a number rather than bluff one.

What they won’t do is give guidance of any kind — “we don’t give guidance, it’s all going to be positive” — or break out product-level revenue or peptide-customer detail. That’s policy, applied consistently, not evasion on any single issue.

The capital-allocation read this year is the clearest signal. The ₹665 crore raise (part to the promoter, part QIP) was used to slash net debt rather than splurge — a conservative, balance-sheet-first instinct. The flip side: the dividend payout stays deliberately low (~7%) because earnings are reinvested into capacity, and there’s no stated framework — no ROCE target, no buyback policy. The philosophy has to be read off behaviour: modest leverage, steady reinvestment up the value chain, active portfolio pruning (Europe subsidiary dissolved, a peptides entity created). The standout risk discipline was on the Senn peptide CDMO acquisition — management insisted capex is demand-linked, “we haven’t built capacity ahead of time,” a welcome contrast to companies that build first and pray.

Where It’s Going

The trajectory is genuinely improving, and three bets define the road ahead. GLS at Genome Valley — a new formulations plant that adds 40% dose capacity and, crucially, a second US-cleared source — was the year’s most successful move and is ramping. The peptide CDMO (Swiss firm Senn, ₹550 crore all-in) is the strategic transformation bet: a play on the GLP-1 wave, where the global peptide market could near-double to $130 billion by 2030, paired with an IIT-Hyderabad R&D centre and planned Indian scale-up. It ran losses all year but delivered its promised first positive-EBITDA quarter in Q4 — management now calls it the “fourth pillar” and targets annual profitability in FY27. The US franchise keeps compounding ($40–50 million of added revenue a year), and Europe is scaling fast.

The risks are concrete. The Gagillapur FDA re-inspection is the overhang — it still hadn’t been scheduled by the latest call, more than two years after the original observations, with nine product applications stuck behind it. Management’s response has been prudent de-risking (moving products to GLS and US sites) rather than denial, and the rest of the network cushions the hit — but resolution is the next catalyst and continued delay the standing risk. Beyond that: input-cost inflation with pricing lag, the perennial commodity price erosion in paracetamol, and a working-capital cycle that needs to stop stretching. The thesis works if the complex-product mix keeps enriching and the FDA clears the plant; it’s a quality-but-not-elite generic maker that has reignited, not a fortress.

The Four Checks

Quality & moat (gate). Qualified pass. The moat is real but moderate: vertical integration captures margin three commodity competitors would forfeit, the ADHD/controlled-substances franchise has a genuine DEA-compliance barrier, and scale in PFI is globally rare. But the base is still high-volume generics exposed to price erosion, and ~95% export concentration (de facto US) is a real vulnerability. A good business with a defensible niche, not a wide moat.
Returns on incremental capital & runway. Mid-teens and improving. ROCE is ~16–17% and has walked up steadily; the runway (complex generics, controlled substances, the peptide CDMO, Europe) is decent. But returns aren’t elite (ROE 13.7%), and the heavy working-capital intensity means each rupee of growth ties up a lot of inventory. The peptide bet could lift the return profile if it scales; it’s early.
Capital allocation for the stage. Rational and conservative. Reinvesting into higher-value capacity while returns are mid-teens is appropriate, the demand-linked (not speculative) capex discipline is a real positive, and using the equity raise to deleverage rather than empire-build shows restraint. The low dividend fits a reinvest-for-growth stage. Mild critiques: no explicit allocation framework, and the equity raise diluted holders even as it strengthened the balance sheet.
Price. Demanding. 31× earnings and 3.7× book for a mid-teens-ROE generic maker prices in the FY26 acceleration durably continuing — through the FDA overhang, the input-cost squeeze, and the peptide bet maturing. The business quality is real but not the 20%+-ROE tier that usually earns this multiple. Reasonable to like the franchise; the valuation leaves little cushion if the breakout stalls.

Sources

Concall transcripts read: Q1 FY26 (Aug 2025), Q2 FY26 (Nov 2025), Q3 FY26 (Jan 2026), Q4/FY26 (call 29 Apr 2026).
Annual reports: FY24 and FY23 carried full narrative (note the May-2023 ransomware attack that dented FY24); the FY25 AR extract was boilerplate-only (no Chairman’s message/MD&A), so FY25 strategy is inferred from data + continuity.
Snapshot: screener.in consolidated, fetched 2026-06-09 (logged-out).
Open item flagged: Gagillapur US FDA re-inspection still unscheduled >2 years post-observations; 9 applications pending behind it.
Research dumps: vault/Sources/Earnings/Granules India Ltd/.